Kyowa Kirin, Inc, an affiliate of Japanese pharmaceutical company Kyowa Kirin Co Ltd (TSE: 4151), announced on Friday that it will no longer distribute or fulfill orders for orders for Fareston (toremefine) 60 mg tablets in the United States, effective 31 August 2024.

This move aligns with the firm's Vision for 2030 and its focus on the discovery, development and delivery of novel therapies for patients.

Kyowa Kirin, has notified the US Food and Drug Administration (FDA) and the manufacturer of toremefine tablets, Orion Corporation.

The company is accepting orders for the medicine until 29 August 2024.